Notably, hypermethylation of IGFBP2 precedes the onset of hepatic steatosis in dietary NAFLD models—even when mice are metabolically stable—highlighting its potential as an early biomarker for liver disease risk. Here, IGFBP2 is linked to metabolic dysfunction-associated steatotic liver disease.